What does Kyron.bio do?
Kyron.bio is a glycan engineering startup based in Paris that specializes in advancing therapeutic proteins for cancer, autoimmune disorders, and infectious diseases by controlling the N-glycosylation process.
How much did they raise?
The company raised €5.5m in a funding round led by HCVC with participation from Verve Ventures, Entrepreneur First, and Saras Capital.
What are their plans for the money?
Kyron.bio plans to use the funds to expand its operations and further develop its scalable, plug-and-play glycan engineering platform, which has the potential to improve protein targeting and reduce unwanted immune responses.
What have they achieved so far?
The firm has made significant progress by developing a platform that precisely controls N-glycosylation, thereby enhancing protein function and mitigating immune attacks on therapeutic proteins.
